Compare · ABT vs LEXX
ABT vs LEXX
Side-by-side comparison of Abbott Laboratories (ABT) and Lexaria Bioscience Corp. (LEXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and LEXX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $185.36B, about 1574.3x LEXX ($117.7M).
- Over the past year, ABT is down 18.4% and LEXX is down 60.8% - ABT leads by 42.4 points.
- ABT has been more active in the news (4 items in the past 4 weeks vs 3 for LEXX).
- ABT has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Abbott Laboratories
- Lexaria Bioscience Corp.
- Price
- $106.03-1.04%
- $5.00+4.17%
- Market cap
- $185.36B
- $117.7M
- 1M return
- +10.85%
- -41.00%
- 1Y return
- -18.41%
- -60.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Latest ABT
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
Latest LEXX
- Lexaria Bioscience Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Lexaria Announces Effective Date for Reverse Stock Split
- SEC Form 10-Q filed by Lexaria Bioscience Corp.
- Lexaria Updates Business Development
- Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
- Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
- GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
- Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
- Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
- Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7